Viewing Study NCT05386550

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:56 PM
Ignite Modification Date: 2026-01-24 @ 6:12 PM
Study NCT ID: NCT05386550
Status: TERMINATED
Last Update Posted: 2025-06-13
First Post: 2022-05-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Sponsor: EMD Serono Research & Development Institute, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Head and Neck Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Adjuvant radiotherapy (RT) View
None Stage III View
None Stage IVA View
None Stage IVB View
None Oral cavity View
None Oropharynx View
None Larynx View
None Hypopharynx View
None Unfit View